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Abstract The zebrafish, Danio rerio, has been established
as an excellent vertebrate model for the study of develop-
mental biology and gene function. It also has proven to be a
valuable model to study human diseases. Here, we
reviewed recent publications using zebrafish to study the
pathology of human neurodegenerative diseases including
Parkinson’s, Huntington’s, and Alzheimer’s. These studies
indicate that zebrafish genes and their human homologues
have conserved functions with respect to the etiology of
neurodegenerative diseases. The characteristics of the
zebrafish and the experimental approaches to which it is
amenable make this species a useful complement to other
animal models for the study of pathologic mechanisms of
neurodegenerative diseases and for the screening of com-
pounds with therapeutic potential.
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Introduction
The zebrafish has been widely used as a model for the
study of developmental biology. One major reason for its
popularity is that not only is it a vertebrate and thus closer
to humans than invertebrate models, but it has several
advantages over other vertebrate models. These include
high fecundity (a few hundred eggs per spawning),
transparent embryos, and external development. Zebrafish
can be easily visualized and experimentally manipulated.
Their generation time is short (2–3 months). All these
features, previously found mainly in invertebrate models,
facilitate genetic and high-throughput functional studies.
The straightforward and yet powerful experimental
approaches based on microinjection of antisense morpho-
lino oligonucleotides (MOs) into one-cell stage embryos are
commonly used to temporarily silence zebrafish genes
during the first few days of embryonic development. MOs
are chemically modified oligonucleotides that can specifi-
cally bind to their target mRNAs with more stability and
resistance to endogenous degradations. Their hybridization
to mRNA can block translation when they are targeted to
sequences near the initiation codon. Alternatively, they can
block splicing when targeted to exon-intron boundaries.
This method has proven to be simple, rapid, specific, and
effective [1￿￿]. Another widely used technique in zebrafish
is transgenesis with a fluorescent reporter expressed under
the control of a tissue- or cell-type–specific promoter.
Transgenesis can also be used to overexpress specific genes
or their mutated versions in specific tissues or cell types.
The recent introduction of I-SceI meganuclease or of Tol2
transposon greatly increased the efficiency of transgenesis
in zebrafish [2, 3].
Zebrafish have also proven to be a particularly relevant
vertebrate model for the study of human diseases. Com-
pared with other vertebrate models, screens for zebrafish
mutants are less costly and easier to perform. Large-scale
mutagenesis screens have been performed in zebrafish [4].
Some of the mutants identified in these screens are
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tions to our understanding of human biology. Zebrafish
mutants have allowed a better understanding of various
human conditions including blood disorders, aging, mus-
cular dystrophy, and autism. Here, we review recent
progress in modeling human neurodegenerative disorders
using zebrafish.
Parkinson’s Disease
Although there are some notable differences in structure and
scale between the zebrafish brain and that of humans, the
overall organization shows similarities. Specific regions of
the zebrafish brain can be related to and are often strikingly
conserved when compared with their human counterparts.
For example, the zebrafish ventral telencephalon is sug-
gested to be homologous to the striatum in humans.
Retrograde tracing experiments in adult zebrafish brain
found that dopaminergic (DA) neurons projecting to the
ventral telencephalon are located in the posterior tuberculum
of the ventral diencephalon (vDC). Thus, zebrafish DA
neuron clusters in the vDC are analogous to the ascending
midbrain DA neurons of the mammalian nigrostriatal
pathway [5]. The DA system has been characterized
during embryogenesis in zebrafish. DA neurons are first
detected at about 18 hours post-fertilization (hpf) in a
cluster of cells in the vDC. At 72 hpf, the zebrafish
central nervous system (CNS) development is well
advanced. DA neurons are found mainly in the olfactory
bulb, preoptic region, pretectum, retina, and vDC. Several
mutants with abnormal patternings of DA neuron in the
vDC have been identified in large-scale mutant screens.
Characterization of these mutants suggest that the Shh and
Nodal signaling pathways play key roles in DA neuron
differentiation in zebrafish as they do in mammals.
Transcription factors, including Nurr1/Nr4a2, Pitx3, and
Lmx1b, have been shown to play evolutionarily conserved
roles in the specification of zebrafish DA neurons.
To date, several orthologs of major Parkinson’s disease
(PD)–associated genes have been found in zebrafish,
including parkin, pink1, dj-1, and lrrk2. MO knockdown
and/or transgenic overexpression of mutants of these genes
suggest that they have conserved functions in the develop-
ment and/or survival of DA neurons.
Parkin
Mutations in Parkin are the most common autosomal-
recessive mutations in early-onset PD. Parkin encodes an
E3 ubiquitin ligase involved in the ubiquitin proteasome
degradation system. Parkin is also thought to play critical
roles in mitochondrial function together with other PD-
related genes such as PINK1 and DJ-1. Drosophila models
of parkin loss of function show a loss of DA neurons and
reduced mitochondria with a remarkable loss of cristae [6,
7]. However, parkin-null mice do not develop any DA
neuron loss or mitochondrial or behavioral abnormality [8].
The zebrafish parkin gene encodes a 458 amino acid
protein, which is highly conserved between zebrafish and
humans with overall 62% identity and up to 92% similarity
in its functional domains [9]. Similar to human Parkin,
zebrafish parkin is ubiquitously expressed throughout
embryonic development and in adult tissues. MO knock-
down of parkin resulted in an approximately 20% loss of
DA neurons in the vDC with increased susceptibility to the
PD-inducing neurotoxin 1-methyl-4-phenylpyridinium
(MPP+). Zebrafish with parkin deficiencies did not show
any abnormal mitochondrial morphology, but activity of the
mitochondrial respiratory chain complex I was reduced by
45%. The impairment of the mitochondrial respiratory
chain is also found in the tissues of PD patients with
Parkin mutations. In contrast, a different study showed no
significant loss in diencephalic DA neurons after parkin
knockdown, although DA neurons of the morphant fish
showed an increased vulnerability to stress-induced cell
death [10]. This discrepancy could result from different
knockdown efficiencies of MOs targeted to different
sequences in the zebrafish parkin gene.
Similar to human Parkin, zebrafish parkin is transcrip-
tionally upregulated in response to mitochondrial stress. In
addition, stable overexpression of parkin in transgenic
zebrafish lines protect fish from cell death induced by
proteotoxic stress, suggesting a protective capacity of
parkin in vivo. This implies a potential therapy for PD by
a transcriptional upregulation of endogenous Parkin [10].
Pink1
Mutations in PINK1 (PTEN-induced kinase 1) are the
second most common cause of autosomal-recessive early-
onset PD. PINK1 encodes a ubiquitously expressed protein
with an N-terminal mitochondrial targeting motif and a
conserved serine⁄threonine kinase domain. PINK1 seems to
protect cultures of neurons against mitochondrial dysfunc-
tion and apoptosis induced by stress. In Drosophila, pink1-
deficient mutants had mitochondrial defects leading to
degeneration of flight muscles and mild loss of DA neurons
[11, 12]. Such defects were not observed in mice with
targeted null mutations in pink1 [13, 14]. In zebrafish,
pink1 is expressed ubiquitously and the predicted protein
has 54% amino acid sequence identity to human PINK1.
An initial study reported that MO knockdown of pink1
resulted in a an approximate 40% reduction in the number
of DA neurons in the vDC [15]. However, we and others
have been unable to replicate such a severe phenotype [16,
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resulted from MO-induced effects unrelated to the pink1
gene silencing. Although pink1 knockdown did not cause
large alterations in the number of DA neurons in the vDC,
we observed that the patterning of these neurons and their
projections were perturbed. The pink1 morphants also
showed impaired response to touch stimuli and reduced
swimming behavior [16]. The pink1 knockdown caused
mitochondrial defects such as the loss of cristae and a
reduced number of mitochondria, thus affecting mitochon-
drial function (unpublished data). In addition, the DA neuron
clusters of pink1-deficient zebrafish were more sensitive to
1-methyl-4-phenyl-1,2,3,6-tetrapyridine (MPTP) toxicity
[17]. These results indicate a role for pink1 in DA neuron
development and function in zebrafish.
Developmental defects in DA neurons, resulting from
PINK1 mutations, may also render DA neurons more
susceptible to environmental stress. A pink1 mutant zebra-
fish line with a nonsense mutation in exon 7 (Y431*) was
found in ENU-mutagenesis libraries [18]. This mutation is
predicted to result in a partial Pink1 protein with loss of its C
terminus and part of its kinase domain. Although there were
no obvious behavioral abnormalities, the larvae (5 days post-
fertilization [dpf]) of this line showed a significant decrease in
the number of DA neurons and a reduction in mitochondrial
complex I activity. These phenotypes are similar to those
observed in parkin-deficient zebrafish. These latter observa-
tions further supported the notion that PINK1 and Parkin are
in the same pathway in regulating DA neuron development
and mitochondrial functions, as was previously suggested by
Drosophila PD models.
dj-1
Mutations in DJ-1 lead to rare autosomal-recessive early-
onset PD. DJ-1, a member of the ThiJ/Pfpl/DJ-1 protein
family, is involved in various functions, including its role as
a redox-sensitive chaperone and in mitochondria protection
against oxidative stress. In different Drosophila models
RNA interference-knockdown of DJ-1 led to varying
degrees of degeneration of DA neurons and hypersensitivity
to oxidative stress [8]. However, similar to parkin- or
PINK1-null mice, DJ-1-null mice did not show any major
abnormality in the number of DA neurons in the substantia
nigra pars compacta and in the levels of striatal dopamine
[8]. The zebrafish Dj-1 protein shows 83% overall amino
acid identity to human DJ-1 [19]. The amino acids affected
by pathogenic mutations in PD patients are especially well
conserved in zebrafish Dj-1. It is expressed through
embryogenesis and transcripts are ubiquitously found in
all adult tissues with a relatively higher abundance in the
brain [20]. MO knockdown of dj-1 did not cause a decrease
in number of DA neurons. However, DA neurons in dj-1
morphants were more sensitive to hydrogen peroxide or to
the proteasome inhibitor MG132. They were also more
susceptible to programmed cell death [20, 21]. Upregula-
tion of dj-1 was reported in the brain of zebrafish subjected
to oxidative stress [21]. These findings suggest that DJ-1
has conserved functions in zebrafish and humans. Muta-
tions in DJ-1 may impair the response of DA neurons to
environmental stress and eventually lead to cell death.
lrrk2
Mutations in LRRK2 are the most frequent cause of
autosomal-dominant PD. The LRRK2 gene encodes a large
protein with multiple functional domains, including ankyrin
repeats, one Ser/Thr kinase, and one Roc GTPase enzy-
matic domain, as well as COR and WD40 domains.
In Drosophila, overexpression of LRRK2 led to age-
dependent locomotor dysfunctions and loss of DA neurons
[22, 23]. The mouse transgenic models of LRRK2 (either
WT or mutants) did not show any loss of DA neurons [24,
25]. Zebrafish and human LRRK2 have highly conserved
amino acid sequences and predicted structures [26]. The
zebrafish gene is ubiquitously expressed during embryo-
genesis with more abundance in the brain, and transcripts
are found in multiple tissues and organs of adult fish. The
deletion of the WD40 domain of lrrk2 by splice-blocking
MOs caused a significant loss of DA neurons in the vDC
and locomotor defects. This also resulted in reduced and
disorganized axon tracts, mainly in the midbrain. These
results implicate the WD40 domain of LRRK2 in DA
neuron development consistent with its known functions in
mediating protein-protein interactions and regulation of
LRRK2 kinase activity. Future studies should investigate
the effects of overexpressing lrrk2 (WT or mutant forms) in
transgenic zebrafish.
Zebrafish orthologs of other PD-related genes such as
UCH-L1 and GIGYF2 have also been found [27, 28].
Although several members of the synuclein family have been
found in the zebrafish genome, the zebrafish ortholog of α-
synuclein has yet to be found, suggesting that the α-synuclein
gene may have been lost in zebrafish perhaps due to the
functional redundancy among synuclein family members.
MPTP-Induced Zebrafish PD Model
The majority of PD cases are sporadic forms, which may
suggest a role of environmental factors or more complex
gene-environment interactions. The neurotoxin MPTP,
known to induce PD in humans, has been successfully
used in rodent and primate models of PD. It is thought that
MPTP can interrupt the electron transport chain in
mitochondria at complex I, which will eventually result in
cell death. In adult zebrafish, MPTP induced a transient
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[29]. Earlier studies in larval zebrafish showed a significant
reduction of DA neurons in the vDC following MPTP
treatment [30–32]. More extensive studies suggested that
different groups of DA neurons in the vDC show different
sensitivities to MPTP, with those neurons with ascending
projections being more sensitive [33, 34]. Dopamine levels
also declined after MPTP treatment, which is consistent
with findings in humans. Thus, similar to mammals, MPTP
can induce a significantly functional deficit of DA neurons
in zebrafish.
Together, these studies strongly indicated that the DA
neurons in the vDC of zebrafish are analogous to those in the
mammalian nigrostriatal pathway. Zebrafish orthologs of PD-
related genes have highly conserved functions in the develop-
mentandsurvivalofDAneuronsandinmotorbehavior.Toxin-
induced loss of DA neurons in zebrafish is also a relevant
model of human PD. In the future, more PD-related mutants
will likely be obtained using methods such as TILLING
(targeting induced local lesions in genomes) or ZFN (zinc
finger nucleases). These mutants might greatly facilitate the
screening for small molecules with therapeutic effects.
Huntington’s Disease
Huntington’s disease (HD), an invariably fatal neurodegen-
erative disorder, follows an autosomal-dominant inheritance
pattern of a mutant form of the huntingtin gene (HTT)
coding for an abnormal expansion of a trinucleotide repeat
encoding glutamine (CAG) at the amino terminal of the
HTT protein. The length of the polyglutamine tract
correlates with the penetrance, age of onset, and severity
of HD. At the moment, the normal function of the HTT
gene is not well understood. Despite the ubiquitous
expression of HTT, specific brain areas of HD patients are
affected earlier than others. The neuronal atrophy character-
istics of HD are seen in regions of the striatum (caudate and
putamen) and cortex. Medium spiny neurons of the
striatum, which use γ-aminobutyric acid and project to
the substantia nigra and globus pallidus, are the most
vulnerable to loss [35]. What puts these neurons at risk is
largely unknown.
Zebrafish as a Model for HD
The zebrafish Htt protein shares about 70% identity with
the human HTT ortholog and encodes four glutamines (vs ~
35 glutamines in the normal human HTT) [36]. Zebrafish
could prove to be a useful model, as the early embryonic
death of mice with a targeted null mutation in Htt provide
very limited insight into the role of HTT [37]. Zebrafish
antisense MO knockdown, which provides a deficiency but
not a total depletion of the Htt protein, might be a better
strategy. Observations made in zebrafish htt morphant
implicate wild-type Htt function in cellular iron utilization
[38]. During gastrulation, the htt mRNA is expressed
uniformly throughout the embryo; however, as develop-
ment progresses, its expression decreases in non-neuronal
tissues but remains strong in the head region. In the above
study, a high concentration of MOs resulted in a large
variety of developmental defects (slight growth delay, brain
necrosis, lack of brain ventricle enlargement, and thinned
yolk extension) possibly due to the off-target effects of the
MOs [38]. At lower doses of MO, a thin yolk extension and
blood hypochromia were the most common morphologic
defects remaining and were thus deemed specific. The
hypochromic blood was associated with deficits in hemo-
globin production caused by altered iron metabolism.
Making iron available to the embryo restored hemoglobin
production in Htt-deficient embryos. Signs of iron deficiency
including defects in iron homeostasis and energy metabolism
are features of HD pathogenesis [39]. Thus, polyglutamine
tract expansion in the wild-type huntingtin protein may alter
its normal function in the metabolism of iron leading to HD
pathology. Results from this study highlight the fact that MOs
can be used successfully to produce specific phenotypes when
attention is paid to the dosage.
Using the same Htt-deficient zebrafish model, Henshall
et al. [40] focused on CNS defects to explain the specificity
of neuropathology in HD brains. Although htt is ubiqui-
tously expressed in the zebrafish brain, it seems to have a
specific function within the forebrain that enables formation
of telencephalic progenitor cells and preplacodal cells.
Because the zebrafish telencephalon is believed to house
the structures analogous to the human striatum, this study
may have found a way of implicating a striatal-specific loss
of medium-sized spiny neurons to the expression of Htt
protein. Zebrafish deficient in Htt lose placode-derived
tissue including olfactory and lateral line sensory neurons
and have a reduction in telencephalic tissue. The finding
that sensory neurons are perturbed by the reduction of Htt
in the zebrafish model is consistent with the clinical
observation that HD patients present with impaired olfac-
tory function [41]. Therefore, it may be the loss of normal
htt function that contributes to the symptoms of HD
pathology, and not exclusively the toxic gain-of-function
caused by an expansion of the polyglutamine tract.
Another in vivo study investigating Htt loss-of-function
in zebrafish observed massive apoptosis of neuronal cells
by 24 hpf, which was accompanied by impaired neuronal
development, small eyes, and heads, as well as an
enlargement of brain ventricles [42]. Later in development,
these Htt-deficient zebrafish develop lower jaw abnormal-
ities with most branchial arches missing. Most notably,
brain-derived neurotrophic factor (BDNF) expression was
Curr Neurol Neurosci Rep (2011) 11:274–282 277reduced. BDNF enhances the differentiation of sensory and
sympathetic neurons. The observation that Htt-MO and
BDNF-MO produce similar phenotypes suggests that Htt
regulates BDNF function. Moreover, treatment of Htt-
deficient embryos with exogenous BDNF significantly
rescued these defects. Thus, increasing expression of the
prosurvival neurotrophin, BDNF, could be a therapeutic
approach in the treatment of HD.
Inhibition of Polyglutamine Protein Aggregation
Schiffer et al. [43] exploited the aqueous environment of
the zebrafish and the lack of its blood–brain barrier in early
development to facilitate the screening of compounds that
may lessen the toxicity of mutant Htt (mHtt) aggregates. As
opposed to cell culture experiments, zebrafish allow for the
evaluation of drugs at the whole organism level, making it
possible to assess potential side effects. In HD patients,
long polyglutamine tracts are found in inclusions within
brain tissue. The intracellular deposition of these inclusions
is associated primarily with the degeneration of neurons in
the striatum. In a zebrafish HD model transiently express-
ing 102 polyglutamine repeats in the N-terminal fragment
of the huntingtin protein fused with GFP (Q102-GFP), this
mutant protein accumulates in inclusion body-like aggre-
gates throughout the body of embryos at 24 hpf. The
soluble Q102-GFP protein translocated from the cytoplasm
to inclusion bodies. Q102-GFP expression resulted in an
increase in embryonic lethality or in embryos with
abnormal morphology. Embryonic lethality was shown to
be accompanied by apoptosis. Upon closer examination, it
was seen that almost all apoptotic cells lacked inclusions.
Likewise, almost all cells containing inclusions were
nonapoptotic. Thus, it seems that soluble mHtt forms are
neurotoxic, whereas insoluble inclusions containing mHtt
aggregates are not. It was also shown that aberrantly folded
Q102-GFP aggregates can be cleared by heat-shock
proteins and lead to the reduction of apoptotic cells and
embryonic death. This HD model’s amenability to testing
compounds that could inhibit Q102-GFP aggregation in
vivo retrieved four inhibitors of Q102-GFP aggregation
(PGL-135, Congo red, 293G02, and 306H03).
A separate study generated a stable transgenic zebrafish
line expressing a Q71-GFP fusion protein under the control of
therhodopsinpromoter,whichwasusedtoscreenandidentify
compounds that reduce aggregates [44]. Thus, zebrafish have
proven to be a valuable model system for the screening and
identification of putative therapeutic compounds.
Rhes
Perhaps the key to the specific neuronal atrophy of striatal
neurons in HD is the identification of a factor that is
exclusive to these affected neurons. It has been suggested
that the cytotoxic targeting of mHtt to striatal neurons is
amplified by interactions with a mainly striatal protein
called Rhes [45￿]. Cell culture experiments have shown that
Rhes induces sumoylation of mHtt, which increases the
amount of soluble mHTT, thus reducing mHtt aggregation.
It has been found that disaggregated mHTT protein clumps
are more neurotoxic than the mHTT aggregates [45￿]. In an
HD transgenic mouse model expressing mHTT [46], Rhes
preferentially binds the striatal mHTT over the wild-type
HTT protein [45￿]. Cell culture studies using HEK293 cells,
striatal cells, and differentiated neuronal PC12 cells reveal
that the presence of Rhes reduces cell survival when mHTT
is present. This mHTT-mediated reduction in cell survival
was rescued by blocking Rhes with RNA interference.
Because HD diagnosis can precede the onset of
symptoms, the search for drugs that block the binding of
Rhes to mHTT or that block Rhes clumps from disaggre-
gating is worthwhile and can be achieved using zebrafish to
perform high-throughput small molecule screens. At the
moment, more studies should be done to investigate unique
features of the affected brain areas to move toward the root
cause of why specific neurons are affected despite mHTT
being expressed in all cells of the body.
Two possible orthologs of human Rhes in zebrafish have
been annotated by Ensembl (Zv9): A4IGH1_DANRE on
chromosome 1 and zgc:114118 on chromosome 3. Research
into the functional characterization of the two proteins
would be useful to determine if the interaction between
zebrafish Rhes and mHTT is conserved. A transgenic
zebrafish line expressing human mHTT-GFP or an equiv-
alent zebrafish mHTT-GFP gene in which to examine the
CNS effects of the knockdown of zebrafish Rhes may
prove insightful. Questions that remain to be answered are:
Following Rhes knockdown in zebrafish, would mHTT
disaggregation decrease and if so, would the reduction in
mHTT disaggregation correlate with a reduction in striatal
neuron loss? Can compounds be identified that favor the
aggregated form of mHTT over the soluble cytotoxic form
in zebrafish?
Current treatments focus on reducing the symptoms of
HD, but no drug has been shown to slow the progression of
the disease. The field would benefit from transgenic
zebrafish models expressing the mutant polyglutamine
(>35 CAG repeats) form of the human HTT protein fused
to GFP in a zebrafish htt-null mutant background. Such a
mutation could be obtained by screening for a nonsense
mutation in the zebrafish htt gene by TILLING. This model
would facilitate the study of the toxicity of human mHTT in
its soluble versus aggregated form. Moreover, labeling of
striatal medium spiny neurons in these fish would allow for
performance of high-throughput screens for agents that
would stop or slow the atrophy of the striatal medium spiny
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fish models obtained by MO knockdown could be done.
Alzheimer’s Disease
The pathologic hallmarks of Alzheimer’s disease (AD) are
extracellular amyloid-β (Aβ) protein-containing neuritic
plaques and intracellular hyperphosphorylated tau-containing
neurofibrillary tangles. Early-onset AD is associated with
mutations in three genes involved in Aβ proteolysis display-
ing autosomal-dominant inheritance patterns in humans:
amyloid-β precursor protein (APP), Presenilin 1 (PSEN1),
and Presenilin 2 (PSEN2). Late-onset AD is linked to a
number of genetic risk factors including the apolipoprotein E
(ApoE), which is a cholesterol transport protein, and the
neuronal sortilin-related receptor (SORL1), which acts as a
sorting receptor for APP.
In humans, APP undergoes post-translational processing.
If APP is cleaved by α-secretase, a benign Aβ peptide is
produced. Alternatively, APP can undergo two sequential
cleavages by β-secretase and γ-secretase to generate the
pathogenic Aβ peptide pushing it toward the late endo-
somal pathway. Depending on where the γ-secretase
cleaves the Aβ C-terminal, either Aβ42 or Aβ40 will be
generated. Aβ42 is the longer form of Aβ, which is more
cytotoxic than the shorter Aβ40 peptide.
According to the amyloid hypothesis, deposits of Aβ
outside the neuron are the underlying cause of AD. The
competing tau hypothesis states that the hyperphosphory-
lated tau protein, which forms neurofibrillary tangles inside
neurons, is the catalyst for AD disease progression. This
leads to the disassembly of microtubules essential for
neuronal transport, disrupting neurotransmitter communica-
tion between neurons, and ultimately resulting in cell death.
Zebrafish as a Model for AD
Several of the human genes encoding the enzymes required
for the post-translational modifications of APP have been
found with a high percent of amino acid similarity in
zebrafish. Zebrafish have two genes similar to human APP:
appa and appb [47]. During gastrulation, both app genes
are expressed in the entire embryo, whereas at 24 hpf, the
appa and appb paralogs are expressed in the telencephalon,
the vDC, the trigeminal ganglia, and the posterior lateral
line ganglia. Orthologs of the β-secretase and γ-secretase
complexes are found in zebrafish and are expressed in the
CNS [48, 49]. Despite conservation of the Aβ domain and
of the secretases between zebrafish and humans, a zebrafish
Aβ peptide has yet to be found and it is not known if the
above post-translational modifications that occur in human
APP processing also occur in zebrafish.
Loss of zebrafish Appa and Appb function by MO
knockdown resulted in reduced body length and defective
convergent-extension movements during gastrulation [50].
Interestingly, these defects are rescued by wild-type human
APP mRNA, but not by the Swedish mutant APP, known to
cause familial AD. Both zebrafish psen1 and psen2 are
expressed ubiquitously during embryogenesis; however,
psen2 is more restricted to the CNS, eye, and spinal cord
at 1 dpf [48, 49]. One ortholog of the human β-secretase
enzyme has been annotated by Ensembl (Zv9) in zebrafish:
BACE1 on chromosome 15. Further characterization of this
gene in zebrafish is required to determine if it functions
similarly in zebrafish as it does in humans. Another
candidate gene that requires more in-depth characterization
is the ApoE ε4 susceptibility gene, whose function in
zebrafish is not well understood. ApoE is expressed in the
zebrafish eyes, and some cells of the mesencephalic,
telencephalic, and rhombencephalic brain areas, suggesting
that it may play a significant function in the CNS [51].
Tau
To understand how the microtubule-associated protein tau
(MAPT) contributes to tau pathology and how tau redis-
tributes from neuronal axons to neuronal soma forming
pathogenic neurofibrillary tangles, a zebrafish model
transiently expressing mutant human tau has been reported
[52]. In this study, human tau carrying mutations at sites
associated with hereditary dementias was fused to GFP
while under the control of the zebrafish pan-neural–specific
GATA-2 promoter. GFP-positive neurons were found in the
brain, retina, and spinal cord. In the brain, there was
evidence of hallmark AD-associated cytoskeletal pathology,
including disruption of tau trafficking and cytoskeletal
filaments in the axon, accumulation of tau in the cell body
near the axon, accumulation of fibrillar tau throughout the
cell body, and presence of hyperphosphorylated tau.
Despite showing that mutant human tau-GFP is hyper-
phosphorylated and could be used to monitor the formation
of tangles, this strategy failed to generate a transgenic line
stably expressing tau-GFP.
Bai et al. [53] established a stable transgenic zebrafish
line expressing either GFP or mutant human 4-repeat tau
under the control of the zebrafish enolase-2 promoter, Tg
(eno2:GFP)o rT g ( eno2:Tau), respectively. Zebrafish
enolase-2 was chosen because its expression in differenti-
ated neuronal axons starts after the early stages of zebrafish
development. This prevents pathogenic tau from disrupting
the development of neuronal precursors and from causing
defects that are not attributable to late-onset neurodegener-
ation. In Tg(eno2:Tau) zebrafish, tau was expressed
throughout the CNS and accumulations were present in
the retina, spine, axons, and neuronal soma throughout the
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the examination of pathologic tau in the age-related
progression of AD.
Stable transgenic zebrafish expressing human tau with a
mutation (TAU-P301L) found in frontotemporal dementia
has been generated [54￿￿]. TAU-P301L is expressed in
zebrafish neurons using the Gal4-UAS system, where
DsRed and TAU-P301L are expressed concomitantly in
early neuronal cells (under the control of the zebrafish HuC
promoter), permitting the observation of red tau-expressing
cell in embryos. TAU-P301L expression showed pathologic
features of tauopathies, including human tau hyperphos-
phorylation, tangle formation, and neurodegeneration in the
spinal cord. Moreover, tau-expressing embryos have be-
havioral deficits in escape response after touch stimulus.
This study also reported testing of inhibitors of the tau
kinase GSK3β, which lead to reduced tau phosphorylation
in vivo. Thus, this model serves as a valuable tool to study
AD and related tauopathies in vivo, especially because tau
hyperphosphorylation developed within only 32 h.
SORL1
It has been shown that APP can be diverted away from the
late endosomal pathway by a SORL1-dependent switch,
which sequesters APP into recycling endosomes, prevent-
ing the formation of Aβ [55￿]. Reduced expression of
SORL1 is seen in AD brain tissue and is associated with an
increase in Aβ production [56]. This genetic association
between AD and SORL1 expression is a result of single
nucleotide polymorphisms (SNPs) found within the SORL1
gene [55￿]. It has been demonstrated that SORL1 binds
directly to APP and differentially regulates the sorting of
APP into the late endosomal pathway leading to the
production of cytotoxic Aβ or into the retromer recycling
pathway, sequestering APP from the β- and γ-secretases.
The overexpression of SORL1 in HEK cells reduces Aβ
production by 82%, likely by diverting APP into the
retromer recycling pathway. Controversy does exist over
whether or not there is an association between AD and
SORL1. Currently, more research into the link between
SORL1 and late-onset AD risk is necessary. Of potential
benefit in the elucidation of a link between SORL1 and
AD, a gene coding for a Sorl1-like protein is located on
zebrafish chromosome 15, according to the latest Ensembl
version of the zebrafish genome (Zv9). Expression and
function of zebrafish sorl1 have yet to be investigated.
Conclusions
Animal models have proven essential for our understanding
of the biological fundamentals of complex diseases. Here,
we reviewed recent progress on the pathologic study of
human neurodegenerative diseases using zebrafish as a
model. Gene knockdown of zebrafish orthologs or trans-
genic expression of pathogenic genes implicated in human
neurodegenerative diseases arouses the key morphologic,
physiologic, and biochemical abnormalities on specific
neuron groups, which are shared with other animal models
and human patients. This suggested a significant level of
functional conservation between the genes related to human
neurodegenerative diseases and their zebrafish orthologs.
Thus, zebrafish could be a good alternative model in
elucidating the molecular basis of human neurodegenera-
tive diseases. Taking advantage of some unique features of
the zebrafish, we can anticipate its increased adoption as a
vertebrate model for high-throughput drug screening.
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